I bet this won't get into a diet stroke protocol for at least 50 years. I
wonder what the aged part is that is more helpful that non aged garlic?
We'll never know because we have
NO stroke leadership or strategy. You're screwed along with your children and grandchildren.
http://www.ncbi.nlm.nih.gov/pubmed/26764322
Matsumoto S1,
Nakanishi R1,
Li D1,
Alani A1,
Rezaeian P1,
Prabhu S2,
Abraham J1,
Fahmy MA1,
Dailing C1,
Flores F1,
Hamal S1,
Broersen A3,
Kitslaar PH4,
Budoff MJ5.
Abstract
BACKGROUND:
Although
several previous studies have demonstrated that aged garlic extract
(AGE) inhibits the progression of coronary artery calcification, its
effect on noncalcified plaque (NCP) has been unclear.
OBJECTIVE:
This
study investigated whether AGE reduces coronary plaque volume measured
by cardiac computed tomography angiography (CCTA) in patients with
metabolic syndrome (MetS).
METHODS:
Fifty-five
patients with MetS (mean ± SD age: 58.7 ± 6.7 y; 71% men) were
prospectively assigned to consume 2400 mg AGE/d (27 patients) or placebo
(28 patients) orally. Both groups underwent CCTA at baseline and
follow-up 354 ± 41 d apart. Coronary plaque volume, including total
plaque volume (TPV), dense calcium (DC), NCP, and low-attenuation plaque
(LAP), were measured based upon predefined intensity cutoff values.
Multivariable linear regression analysis, adjusted for age, gender,
number of risk factors, hyperlipidemia medications, history of coronary
artery disease, scan interval time, and baseline %TPV, was performed to
examine whether AGE affected each plaque change.
RESULTS:
The
%LAP change was significantly reduced in the AGE group compared with
the placebo group (-1.5% ± 2.3% compared with 0.2% ± 2.0%, P = 0.0049).
In contrast, no difference was observed in %TPV change (0.3% ± 3.3%
compared with 1.6% ± 3.0%, P = 0.13), %NCP change (0.2% ± 3.3% compared
with 1.4% ± 2.9%, P = 0.14), and %DC change (0.2% ± 1.4%, compared with
0.2% ± 1.7%, P = 0.99). Multivariable linear regression analysis found a
beneficial effect of AGE on %LAP regression (β: -1.61; 95% CI: -2.79,
-0.43; P = 0.008).
CONCLUSIONS:
This study
indicates that the %LAP change was significantly greater in the AGE
group than in the placebo group. Further studies are needed to evaluate
whether AGE has the ability to stabilize vulnerable plaque and decrease
adverse cardiovascular events. This trial was registered at
clinicaltrials.gov as
NCT01534910.
No comments:
Post a Comment